84880-03-5

Basic information

• Product Name: Cefpimizole
• Synonyms: CEFPIMIZOLE;Pyridinium, 1-[[(6R,7R)-2-carboxy-7-[[(2R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt;Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt, [6R-[6α,7β(R*)]]-;U 63196;(6R,7R)-7-[[(2R)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfonatoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;1-[[(6R)-2-Carboxylato-7α-[[(R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium;Cefpimizol;cefpimizole:(6r,7r)-7-(((2r)-2-((5-carboxy-1h-IMIDAZOLE-4-carbonyl)amino)-2-phenylacetyl)amino)-8-oxo-3-((4-(2-sulfonatoethyl)pyridin-1-ium-1-yl)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxyli
• CAS NO: 84880-03-5
• Molecular Formula: C28H26N6O10S2
• Molecular Weight: 670.67
• Mol File: 84880-03-5.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cefpimizole(CAS DataBase Reference)
• NIST Chemistry Reference: Cefpimizole(84880-03-5)
• EPA Substance Registry System: Cefpimizole(84880-03-5)

Safety Data

• Hazardous Substances Data: 84880-03-5(Hazardous Substances Data)

Usage

Description

Cefpimizole sodium is a third-generation cephalosporin with a spectrum of activity somewhat narrower than cefotaxime and cefoperazone.

Uses

Antibacterial.

Brand name

Ajicef; Renilan

Antimicrobial activity

A semisynthetic parenteral cephalosporin. It exhibits modest activity compared to other antipseudomonal cephalosporins. Like cefoperazone, it is susceptible to many enterobacterial β-lactamases. In volunteers receiving 0.1–1 g intramuscularly, mean peak plasma concentrations reached 15–20 and 35–40 mg/L, respectively. There was no accumulation when the dose was repeated every 8 h for 7 days. No metabolites have been detected. The plasma elimination half-life is 1.8– 2.1 h. The principal route of elimination is renal, 70–80% being recovered unchanged in the urine. Significant pain at the site of infection has been a prominent adverse event. It is no longer widely available.

InChI:InChI=1/C28H26N6O10S2/c35-23(18(16-4-2-1-3-5-16)31-24(36)19-20(27(38)39)30-14-29-19)32-21-25(37)34-22(28(40)41)17(13-45-26(21)34)12-33-9-6-15(7-10-33)8-11-46(42,43)44/h1-7,9-10,14,18,21,26H,8,11-13H2,(H5-,29,30,31,32,35,36,38,39,40,41,42,43,44)/t18-,21-,26-/m1/s1